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Abstract 
Hypocalcemia is the most common 
complication following total thyroidectomy and 
could be due to direct injury or ischemic damage to 
parathyroid glands during surgery. Hypocalcemia 
adds significantly to hospital stay and cost of 
hospitalisation.  While there are numerous proposed 
treatment algorithms for post-thyroidectomy 
hypocalcemia, there are no universally accepted 
standard guidelines or treatment algorithms 
available. We present a case of prolonged 
recalcitrant hypocalcemia post-total thyroidectomy, 
requiring hospitalisation for more than a month, to 
illustrate the practical problems we faced during 
management of this patient. 
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Introduction 
While hypocalcemia is the most common 
documented complication post-total thyroidectomy, 
hypocalcemia requiring prolonged hospitalisation 
and intravenous (IV) calcium supplementation is 
relatively rare. Hypocalcemia occurs due to 
manipulation of parathyroids during surgery, 
devascularisation, venous engorgement or 
accidental removal.1 The incidence of temporary 
and permanent hypocalcemia is reported to be 
around 27% and 1% respectively.2 Since the risk of 
reactionary/secondary haemorrhage after 24 hours 
of thyroidectomy is very rare, symptomatic 
hypocalcemia is the main reason for prolonged 
hospitalisation post-thyroidectomy.3 
The pre-operative factors associated with 
post-thyroidectomy hypocalcemia are still unclear 
and various scoring systems have been proposed to 
identify patients likely to develop post-operative 
hypocalcemia.4 Identification of at-risk patients 
allows earlier and more aggressive calcium 
correction regimens allowing for shorter hospital 
stays and invasive investigations in low-risk 
patients.  
Feeling of ‘heat waves’ are a documented 
adverse effect of IV calcium gluconate, especially 
when given rapidly. We could not find any 
literature linking either severe thrombophlebitis or 
high-grade fever with IV calcium injections. 
However, this is the second patient in our institute 
to develop high spiking fever coinciding with IV 
calcium injections.  
Case report 
A 39-year-old woman presented with 
thyromegaly and features suggestive of 
hyperthyroidism. She was worked up for the same 
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and diagnosed to have a multinodular goiter (MNG) 
with secondary thyrotoxicosis. Hyperthyroidism 
was controlled with carbimazole, thyroid status was 
optimised and patient was posted for total 
thyroidectomy. Intra-operatively, parathyroid 
glands were not identified and inferior thyroid 
artery branches were ligated and divided after 
crossing the recurrent laryngeal nerve (subcapsular 
vascular ligation). Intra-operative period was 
uneventful, patient was extubated and shifted to 
post-operative ward. 
In the evening following thyroidectomy, 
patient complained of tingling in the fingers. On 
examination, Trousseau’s sign was present (Figure). 
Figure 1: Bilateral carpal spasm 
Blood calcium levels were low, hence IV 
calcium gluconate bolus (10ml of 10% calcium 
gluconate in 100 ml 0.9% Saline) was given. 
Symptoms subsided but reappeared the next 
morning. Patient was started on thrice daily IV 
calcium boluses, however symptoms persisted and 
additional calcium boluses had to be given as 
needed. Patient also developed high spiking fever, 
for which she was worked up, and no evident 
source could be identified. Fever spikes coincided 
with IV calcium injections and patient developed 
pain and swelling around IV lines. A diagnosis of 
thrombophlebitis was made and IV lines were 
changed. Fever abated temporarily but reappeared 
the next day. IV lines were changed frequently and 
external jugular vein (EJV) cannulated but fever 
persisted. Oral calcitriol (0.25 mcg BD) and 
calcium carbonate was given (1.5 gm Q6H), 
supplemented with 6 glasses of milk daily. 
Phosphate and magnesium levels were assessed and 
found to be normal. Parathormone (PTH) was 
assessed and found to be low (7.6 pg/ml; normal: 
15-65pg/ml). Vitamin D levels were assessed and
found to low (22.36 ng/ml; normal: >30 ng/ml).
Histopathology examination of thyroidectomy
specimen did not reveal any parathyroid tissue.
In view of frequent episodes of symptomatic 
hypocalcemia requiring additional IV calcium 
bolus, 1% IV calcium infusion (50 ml of 10% 
calcium gluconate in 450 ml saline) was started at 
50 ml/hour. Though hypocalcemic episodes 
subsided, patient continued to have high spiking 
fever. Broad spectrum antibiotics were started and 
antipyretics were given. Fever abated for a few 
days, but reappeared. Patient developed episodes of 
symptomatic hypocalcemia whenever an attempt to 
taper calcium infusion was made. Hence treatment 
was altered: oral calcium reduced to 4g/day, oral 
calcitriol increased to 1.50 mcg (0.75mcg BD) 
daily, low dose hydrochlorthiazide (12.5 mg) added 
and salt restriction was advised. Calcium infusion 
was gradually tapered and stopped, and replaced 
with IV calcium boluses that were also gradually 
tapered and stopped. Patient did not have any 
further attacks of hypocalcemia or fever. 
Patient was started on oral Vitamin D (60,000 
IU once fortnightly), urine calcium and serum 
phosphate were assessed and calcitriol was reduced 
to 1.00 mcg/day and was discharged from the 
hospital after 46 days post-thyroidectomy. 
Patient has since come for 5 follow-up visits. 
Serum calcium has stabilized and hence oral 
calcium supplementation was reduced. Calcitriol 
was gradually tapered and stopped. Oral Vitamin D 
was reduced to 60,000 IU monthly. Patient is 
currently doing well, with no constipation, fever or 
any symptoms suggestive of hypocalcemia. 
Discussion 
Severe hypocalcemia is one of the life-
threatening complications post-thyroidectomy. The 
initial features of perioral numbness and tingling of 
fingers which often go unnoticed, can prove fatal 
due to cardiac arrest if prompt action is not taken at 
the appropriate moment. 
Post-op hypocalcemia can be transient (lasting 
<12 months) or permanent, in which medical 
supplementation is required for more than 12 
months9. Post-thyroidectomy hypocalcemia may be 
asymptomatic, termed ‘lab hypocalcemia’ or 
symptomatic. Symptomatic hypocalcemia, severe 
hypocalcemia (corrected calcium <7.5mg/dl, <1.87 
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mmol/L) or hypocalcemia associated with ECG QT 
prolongation warrants hospitalisation and 
immediate IV calcium supplementation. Initial 
correction by bolus of 10 ml of 10% calcium 
gluconate in 50-100 ml 0.9% Saline/5% dextrose 
should be urgently administered in all cases of 
symptomatic hypocalcemia over 20 minutes, as 
more rapid infusion can cause lethal cardiac 
dysfunction.3,5 It is recommended that this be 
followed by IV calcium infusion regimen, as this 
bolus will only correct the calcium levels for 2-3 
hours.6 
Accurate prediction of which patients will 
develop this complication is difficult, leading to 
unnecessary long hospitalisation to monitor for this 
rather rare complication. A meta-analysis published 
by Edafe et al1 identifies these factors as 
independent predictors of post-thyroidectomy 
hypocalcemia: (a) identification of <2 parathyroids 
during surgery; (b) reoperation for bleeding; (c) 
corrected calcium <7.5mg/dl or <1.87 mmol/L 24 
hours post-surgery; (d) Graves’disease; (e) heavier 
thyroid specimens. An accurate risk stratification 
would allow for earlier and more aggressive 
institution of calcium correction regimens, possibly 
reducing hospital stay. This would also reduce 
unnecessary supplementation and investigations in 
the majority of patients who would not develop 
hypocalcemia. Albuja-Cruz et al4 have proposed a 
risk stratification protocol (Table 1). In this 
prospective study, the above-mentioned protocol 
was applied to 120 patients, demonstrating a 
significant reduction in calcium supplementation 
(P≤0.001) and hypocalcemic events (P=0.008). 
However, this protocol requires routine 
measurement of pre-and post-operative PTH levels, 
an expensive test that may not be justified given the 
low incidence of persistent, severe hypocalcemia. 
Another prospective study by Arer et al5 on 106 
patients demonstrated that routine calcium 
supplementation can prevent early hypocalcemia 
post-thyroidectomy. A retrospective study by 
Maxwell et al6 confirms that routine 
supplementation of calcium and Vitamin D were 
associated with reduced cost and duration of 
hospitalisation with fewer episodes of 
hypocalcemia.  
Recalcitrant hypocalcemia patients not 
responding to conventional doses of active vitamin 
D analogues (calcitriol or 1-alpha calcidol) and oral 
calcium, and requiring prolonged IV calcium are 
exceptionally rare. Treatment options for such 
patients include addition of thiazide diuretic and use 
of recombinant PTH. Thiazide diuretics also serve 
to offset the dose limiting side effect of Vitamin D 
and calcium supplementation: nephrocalcinosis due 
to increased renal calcium loss in the absence of the 
resorbptive effects of PTH on the renal tubules.7
Table 1: Proposed risk stratification protocol 
Recombinant PTH (rPTH) is expensive, and 
there are no controlled trials demonstrating its 
effectiveness or safety in the setting of post-
thyroidectomy hypocalcemia. However, it has a 
lower incidence of hypercalciuria, significantly 
reduces calcium and calcitriol requirement. A 
prospective phase 2 randomised trial by McLeod et 
al8 on 26 patients demonstrated that rPTH may 
prevent post-thyroidectomy hypocalcemia, shorten 
duration of hospitalisation and reduce the need for 
calcium and Vitamin D on discharge. The drug 
label carries a warning for osteosarcoma although 
this has only been observed in rats, at a dose much 
higher than what is generally used in humans9. The 
cost of this injectable drug limits its use in clinical 
practice and it is only recommended for use in 
patients who cannot attain normocalcemia on oral 
calcium and Vitamin D supplements alone.9 
All patients receiving active vitamin D 
analogues and calcium supplementation should 
have regular monitoring of serum calcium and 
phosphate levels, until values stabilise. The lowest 
dose required to achieve a low-normal serum 
calcium while avoiding hyperphosphatemia should 
be administered. Shorter acting calcitriol should be 
replaced with longer acting vitamin D analogues 
Risk group Recommended 
treatment 
High risk: Post-op PTH 
<10 and/or fall in PTH 
more than 60% from 
pre-op value 
Calcitriol 0.5 mcg 
BD + 6 g calcium 
daily 
Intermediate risk: PTH 
10-19 and/or corrected
calcium <8
3 g calcium daily 
Low risk: PTH >20 
and/or corrected 
calcium >8 
Nil 
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such as cholecalciferol to simplify dosing. Also, 
urine calcium should be maintained less than 300 
mg/24 hours to prevent nephrocalcinosis that can 
result in chronic kidney disease. This case 
highlights the significant morbidity and difficulty 
faced in managing a relatively simple complication. 
Accurate prediction and early institution of 
treatment could possibly reduce length of 
hospitalisation.  
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